ArticleBMC cancer2025
Photodynamic therapeutic activity of novel porphyrins against lung squamous cell carcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Porphyrins, as drug-food homologous bioactive substances, hold significant potential in nanomedicine research and photodynamic therapy (PDT). In this study, we synthesized two novel porphyrin compounds, PTA and PTBA, based on the porphyrin compound TCPP. Using these compounds, we prepared metal-porphyrin nanoparticles and evaluated their properties. Results from multiple assays demonstrated that both PTA and PTBA exhibited significantly enhanced photodynamic therapeutic activation under laser irradiation compared to TCPP. This included improved reactive oxygen species (ROS) and singlet oxygen release, as well as superior antitumor activity. When prepared as metal-porphyrin nanoparticles, all three compounds-PCN224 (TCPP with Zr⁴⁺), PMOF01 (PTA with Zr⁴⁺), and PMOF02 (PTBA with Zr⁴⁺)-showed significantly upregulated photodynamic therapeutic effects. These nanoparticles induced the accumulation of ROS and singlet oxygen in lung squamous cell carcinoma (LSCC) cells and demonstrated both in vitro and in vivo antitumor activity under laser irradiation. Notably, PMOF01 and PMOF02 exhibited much stronger antitumor effects compared to PCN224 in LSCC cells. Our findings highlight the photodynamic therapeutic potential of these novel porphyrin compounds and their nanoparticles. These results not only expand our understanding of porphyrins' antitumor capabilities but also provide new options for PDT applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.